Data / Drug companies / Divi's Laboratories Limited
Divi's Laboratories Limited: 49 products in the FDA NDC directory, labeler code 62331
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Divi's Laboratories Limited (labeler code 62331) lists 49 products in the FDA National Drug Code Directory. By type: 49 bulk ingredients. Its main marketing category is bulk ingredients. The newest product started marketing on April 10, 2026.
The request: Watch Divi's Laboratories Limited (FDA labeler code 62331): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 62331
- Products in commercial distribution
- 49
- Packages
- 49
- Finished drugs by generic name
- 0
- Prescription products
- 0
- Over the counter products
- 0
- Controlled substance products
- Schedule V 2
- Started marketing in the last 12 months
- 3
- Earliest marketing start
- October 3, 1997
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Bulk ingredients | 49 | 100% |
Products by type
| Type | Products | Share |
|---|---|---|
| Bulk ingredients | 49 | 100% |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Powder | 49 | 100% |
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Valacyclovir hydrochloride | 62331-034 | Powder | Bulk ingredients | April 10, 2026 |
| Xanomeline tartrate | 62331-069 | Powder | Bulk ingredients | April 9, 2026 |
| Nabumetone | 62331-008 | Powder | Bulk ingredients | November 17, 2025 |
| Foscarbidopa | 62331-068 | Powder | Bulk ingredients | June 24, 2025 |
| Foslevodopa | 62331-067 | Powder | Bulk ingredients | June 24, 2025 |
| Mesalamine | 62331-064 | Powder | Bulk ingredients | September 19, 2022 |
| Mesalamine | 62331-064 | Powder | Bulk ingredients | September 19, 2022 |
| Iohexol | 62331-066 | Powder | Bulk ingredients | July 4, 2022 |
| Ticagrelor | 62331-065 | Powder | Bulk ingredients | June 27, 2022 |
| Molnupiravir | 62331-063 | Powder | Bulk ingredients | May 6, 2021 |
| Lacosamide | 62331-062 | Powder | Bulk ingredients | September 21, 2020 |
| Mesalamine | 62331-060 | Powder | Bulk ingredients | March 2, 2015 |
| Olmesartan medoxomil | 62331-056 | Powder | Bulk ingredients | November 21, 2012 |
| Pregabalin | 62331-057 | Powder | Bulk ingredients | September 7, 2012 |
| Alexidine dihydrochloride | 62331-053 | Powder | Bulk ingredients | August 31, 2010 |
| Irbesartan | 62331-051 | Powder | Bulk ingredients | March 29, 2010 |
| Lamotrigine | 62331-047 | Powder | Bulk ingredients | March 5, 2010 |
| Valsartan | 62331-050 | Powder | Bulk ingredients | January 28, 2010 |
| Sumatriptan | 62331-048 | Powder | Bulk ingredients | June 24, 2009 |
| Sumatriptan succinate | 62331-049 | Powder | Bulk ingredients | April 2, 2009 |
| Venlafaxine hydrochloride | 62331-044 | Powder | Bulk ingredients | June 9, 2008 |
| Raltegravir potassium | 62331-055 | Powder | Bulk ingredients | May 28, 2008 |
| Orlistat | 62331-045 | Powder | Bulk ingredients | April 23, 2008 |
| Capecitabine | 62331-043 | Powder | Bulk ingredients | August 29, 2007 |
| Vigabatrin | 62331-042 | Powder | Bulk ingredients | August 18, 2007 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.